Cannabinoids in treatment-resistant epilepsy: A review

Area of Science:

• Neurology
• Pharmacology

Background:

• Treatment-resistant epilepsy (TRE) affects 30% of epilepsy patients, leading to significant morbidity and mortality.
• Cannabis-based therapies, including cannabidiol (CBD), have a long history of use for epilepsy.
• Recent placebo-controlled trials (RCTs) provide data on CBD, a cannabis derivative, for epilepsy treatment.

Purpose of the Study:

• To review the current data on the safety and efficacy of CBD in treating epilepsy, focusing on children with Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS).
• To highlight the importance of placebo response in medical cannabis research.
• To identify the need for more data on artisanal cannabis preparations.

Main Methods:

• Review of placebo-controlled, randomized trials (RCTs) investigating CBD.
• Analysis of open-label studies and Phase 3 RCTs for Epidiolex® (CBD).
• Examination of existing data on medical marijuana (MMJ) preparations.

Main Results:

• RCTs have studied the safety and potential efficacy of CBD in children with DS and LGS.
• Open-label studies and Phase 3 RCTs support the efficacy and adequate safety profile of Epidiolex® (CBD) in various TREs.
• Significant gaps exist in data regarding the safety, efficacy, and dosing of artisanal cannabis preparations.

Conclusions:

• CBD demonstrates potential as a treatment for specific types of epilepsy, particularly in pediatric populations.
• Rigorous clinical trials are crucial for understanding the therapeutic role of cannabis derivatives.
• Further research is essential to validate the use and safety of diverse cannabis preparations for epilepsy.